Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies

Zhiwei Yu, Titus J. Boggon, Susumu Kobayashi, Cheng Jin, Patrick C. Ma, Afshin Dowlati, Jeffrey A. Kern, Daniel G. Tenen, Balázs Halmos

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer derive significant clinical benefit from treatment with the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Secondary EGFR mutations such as EGFR T790M commonly lead to resistance to these agents, limiting their long-term efficacy. Irreversible EGFR inhibitors such as CL-387,785 can overcome resistance and are in clinical development, yet acquired resistance against these agents is anticipated. We carried out a cell-based, in vitro random mutagenesis screen to identify EGFR mutations that confer resistance to CL-387,785 using T790M-mutant H1975 lung adenocarcinoma cells. Mutations at several residues occurred repeatedly leading to functional resistance to CL-387,785. These variants showed uninhibited cell growth, reduced apoptosis, and persistent EGFR activation in the presence of CL-387,785 as compared with parental H1975 cells, thus confirming their role in resistance. A screen of alternative agents showed that both an alternative EGFR inhibitor and a cyclin-dependent kinase 4 inhibitor led to significant inhibition of cell growth of the resistant mutants, suggestive of potential alternative treatment strategies. These results identify novel mutations mediating resistance to irreversible EGFR inhibitors and reveal alternative strategies to overcome or prevent the development of resistance in EGFR-mutant non-small cell lung cancers.

Original languageEnglish (US)
Pages (from-to)10417-10427
Number of pages11
JournalCancer Research
Volume67
Issue number21
DOIs
StatePublished - Nov 1 2007

Fingerprint

Epidermal Growth Factor Receptor
Lung Neoplasms
Therapeutics
Mutation
Non-Small Cell Lung Carcinoma
Cyclin-Dependent Kinase 4
Growth
Mutagenesis
Protein-Tyrosine Kinases
Apoptosis
CL 387785

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Yu, Zhiwei ; Boggon, Titus J. ; Kobayashi, Susumu ; Jin, Cheng ; Ma, Patrick C. ; Dowlati, Afshin ; Kern, Jeffrey A. ; Tenen, Daniel G. ; Halmos, Balázs. / Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. In: Cancer Research. 2007 ; Vol. 67, No. 21. pp. 10417-10427.
@article{3c14caa1f88a4bf1b54e8a8e6c87ec7c,
title = "Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies",
abstract = "Patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer derive significant clinical benefit from treatment with the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Secondary EGFR mutations such as EGFR T790M commonly lead to resistance to these agents, limiting their long-term efficacy. Irreversible EGFR inhibitors such as CL-387,785 can overcome resistance and are in clinical development, yet acquired resistance against these agents is anticipated. We carried out a cell-based, in vitro random mutagenesis screen to identify EGFR mutations that confer resistance to CL-387,785 using T790M-mutant H1975 lung adenocarcinoma cells. Mutations at several residues occurred repeatedly leading to functional resistance to CL-387,785. These variants showed uninhibited cell growth, reduced apoptosis, and persistent EGFR activation in the presence of CL-387,785 as compared with parental H1975 cells, thus confirming their role in resistance. A screen of alternative agents showed that both an alternative EGFR inhibitor and a cyclin-dependent kinase 4 inhibitor led to significant inhibition of cell growth of the resistant mutants, suggestive of potential alternative treatment strategies. These results identify novel mutations mediating resistance to irreversible EGFR inhibitors and reveal alternative strategies to overcome or prevent the development of resistance in EGFR-mutant non-small cell lung cancers.",
author = "Zhiwei Yu and Boggon, {Titus J.} and Susumu Kobayashi and Cheng Jin and Ma, {Patrick C.} and Afshin Dowlati and Kern, {Jeffrey A.} and Tenen, {Daniel G.} and Bal{\'a}zs Halmos",
year = "2007",
month = "11",
day = "1",
doi = "10.1158/0008-5472.CAN-07-1248",
language = "English (US)",
volume = "67",
pages = "10417--10427",
journal = "Cancer Research",
issn = "0008-5472",
number = "21",

}

Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. / Yu, Zhiwei; Boggon, Titus J.; Kobayashi, Susumu; Jin, Cheng; Ma, Patrick C.; Dowlati, Afshin; Kern, Jeffrey A.; Tenen, Daniel G.; Halmos, Balázs.

In: Cancer Research, Vol. 67, No. 21, 01.11.2007, p. 10417-10427.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies

AU - Yu, Zhiwei

AU - Boggon, Titus J.

AU - Kobayashi, Susumu

AU - Jin, Cheng

AU - Ma, Patrick C.

AU - Dowlati, Afshin

AU - Kern, Jeffrey A.

AU - Tenen, Daniel G.

AU - Halmos, Balázs

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer derive significant clinical benefit from treatment with the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Secondary EGFR mutations such as EGFR T790M commonly lead to resistance to these agents, limiting their long-term efficacy. Irreversible EGFR inhibitors such as CL-387,785 can overcome resistance and are in clinical development, yet acquired resistance against these agents is anticipated. We carried out a cell-based, in vitro random mutagenesis screen to identify EGFR mutations that confer resistance to CL-387,785 using T790M-mutant H1975 lung adenocarcinoma cells. Mutations at several residues occurred repeatedly leading to functional resistance to CL-387,785. These variants showed uninhibited cell growth, reduced apoptosis, and persistent EGFR activation in the presence of CL-387,785 as compared with parental H1975 cells, thus confirming their role in resistance. A screen of alternative agents showed that both an alternative EGFR inhibitor and a cyclin-dependent kinase 4 inhibitor led to significant inhibition of cell growth of the resistant mutants, suggestive of potential alternative treatment strategies. These results identify novel mutations mediating resistance to irreversible EGFR inhibitors and reveal alternative strategies to overcome or prevent the development of resistance in EGFR-mutant non-small cell lung cancers.

AB - Patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer derive significant clinical benefit from treatment with the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Secondary EGFR mutations such as EGFR T790M commonly lead to resistance to these agents, limiting their long-term efficacy. Irreversible EGFR inhibitors such as CL-387,785 can overcome resistance and are in clinical development, yet acquired resistance against these agents is anticipated. We carried out a cell-based, in vitro random mutagenesis screen to identify EGFR mutations that confer resistance to CL-387,785 using T790M-mutant H1975 lung adenocarcinoma cells. Mutations at several residues occurred repeatedly leading to functional resistance to CL-387,785. These variants showed uninhibited cell growth, reduced apoptosis, and persistent EGFR activation in the presence of CL-387,785 as compared with parental H1975 cells, thus confirming their role in resistance. A screen of alternative agents showed that both an alternative EGFR inhibitor and a cyclin-dependent kinase 4 inhibitor led to significant inhibition of cell growth of the resistant mutants, suggestive of potential alternative treatment strategies. These results identify novel mutations mediating resistance to irreversible EGFR inhibitors and reveal alternative strategies to overcome or prevent the development of resistance in EGFR-mutant non-small cell lung cancers.

UR - http://www.scopus.com/inward/record.url?scp=35948977282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948977282&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-1248

DO - 10.1158/0008-5472.CAN-07-1248

M3 - Article

C2 - 17974985

AN - SCOPUS:35948977282

VL - 67

SP - 10417

EP - 10427

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 21

ER -